Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Stefan Klaus Barta, MD MRCP, MS, Noah Kornblum, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Elizabeth Handorf, Joseph Sparano, MD, Richard Piekarz, MD PhD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2018-99-116991

Published: 2018

Journal Articles

Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis

Catherine Diefenbach, MD, Bruce G. Raphael, MD, Michael L. Grossbard, MD, Kenneth B. Hymes, MD, Tibor Moskovits, MD, David Kaminetzky, MD, Peter Martin, MD, Jia Ruan, MD PhD, Megan McShea, BA, Leonelle B'etou, MPH, Maryam Bonakdar, Cem Abidoglu, Lina Kozhaya, John P. Leonard, MD, Derya Unutmaz, MD

Blood (2016) 128 (22): 2949.

https://doi.org/10.1182/blood.V128.22.2949.2949

Published: 2016

Journal Articles

Long-Term Outcomes Of Splenectomy-Sparing Therapies For Immune Thrombocytopenia

Mala Varma, MD, Michael L. Grossbard, MD

Blood (2013) 122 (21): 4759.

https://doi.org/10.1182/blood.V122.21.4759.4759

Published: 2013

Journal Articles

Comparison Of Distant Relapse Rates Of Immune Thromocytopenia In Patients Treated With Steroids Versus Anti-Rh(D) with/Without Steroids Versus Rituximab with/Without Steroids

Mala Varma, MD, Michael L. Grossbard, MD

Blood (2013) 122 (21): 4760.

https://doi.org/10.1182/blood.V122.21.4760.4760

Published: 2013

Journal Articles

Anti-Rh(D) Utilization Prior To and Following The FDA Mandate For Hemoglobinuria Screening 03/11/10

Mala Varma, MD, Hrvoje Melinscak, MD, Ilan Shapira, MD, Gabriel Sara, MD, Michael L. Grossbard, MD

Blood (2013) 122 (21): 4761.

https://doi.org/10.1182/blood.V122.21.4761.4761

Published: 2013

Journal Articles

Combination of Anti-Rh(D) and Danazol in Patients with Immune Thrombocytopenia

Mala Varma, MD, Ilan Shapira, MD, Ibrahim Nakhoul, MD, Jonah Shulman, MD, David Lucido, PhD, Peter Kozuch, MD, Bruce Culliney, MD, Tahir Mirzoyev, Maria Machuca, Michael L. Grossbard, MD

Blood (2012) 120 (21): 3343.

https://doi.org/10.1182/blood.V120.21.3343.3343

Published: 2012

Journal Articles

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Ibrahim N. Nakhoul, MD, Ilan Shapira, MD, May Abdo-Matkiwsky, MD, Peter Kozuch, MD, Etta Frankel, MD, Sree Bhavani Chalasani, MD, Takhir Mirzoyev, Margaret Dietrich, Peter Homel, PhD, Michael L. Grossbard, MD, Mala Varma, MD

Blood (2006) 108 (11): 3983.

https://doi.org/10.1182/blood.V108.11.3983.3983

Published: 2006

NARROW

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis

Long-Term Outcomes Of Splenectomy-Sparing Therapies For Immune Thrombocytopenia

Comparison Of Distant Relapse Rates Of Immune Thromocytopenia In Patients Treated With Steroids Versus Anti-Rh(D) with/Without Steroids Versus Rituximab with/Without Steroids

Anti-Rh(D) Utilization Prior To and Following The FDA Mandate For Hemoglobinuria Screening 03/11/10

Combination of Anti-Rh(D) and Danazol in Patients with Immune Thrombocytopenia

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only